Methylprednisolone hemisuccinate
- Generic Name
- Methylprednisolone hemisuccinate
- Brand Names
- Solu-medrol
- Drug Type
- Small Molecule
- Chemical Formula
- C26H34O8
- CAS Number
- 2921-57-5
- Unique Ingredient Identifier
- 5GMR90S4KN
- Background
A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.
- Associated Conditions
- Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis
- Associated Therapies
- Palliative Treatment
A Trial of Selinexor, Ruxolitinib and Methylprednisolone
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Oncotherapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT06225310
Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma
Early Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Oncotherapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT06209606
- Locations
- 🇺🇸
Berenson Cancer Center, West Hollywood, California, United States
Glucocorticoid Treatment in Transaortic Valve Replacement to Reduce the Incidence of Conduction Disturbances (GLUCO-TAVR).
Phase 4
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-11
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Hospital General Universitario de Alicante
- Target Recruit Count
- 100
- Registration Number
- NCT06076824
- Locations
- 🇪🇸
General University Hospital of Alicante, Alicante, Spain
Steroid for Treatment of Acute/Subacute Severe Cerebral Venous Thrombosis.
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Xuanwu Hospital, Beijing
- Target Recruit Count
- 170
- Registration Number
- NCT05990894
- Locations
- 🇨🇳
Xuanwu Hospital, Capital Medical University, Beijing, China
Methylprednisolone in Patients With Cognitive Deficits in Post-COVID-19 Syndrome (PCS)
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 418
- Registration Number
- NCT05986422
- Locations
- 🇩🇪
Charité - Universitätsmedizin Berlin, Berlin, Germany
The Prospective Evaluation of Peri-Operative Glucocorticoid Use in the Management of Cervicofacial Infections of Odontogenic Origin
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- University of Manitoba
- Target Recruit Count
- 29
- Registration Number
- NCT05951504
- Locations
- 🇨🇦
University of Manitoba, Winnipeg, Manitoba, Canada
Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Odense University Hospital
- Target Recruit Count
- 195
- Registration Number
- NCT05947669
- Locations
- 🇬🇧
The Royal Marsden Hospital, London, United Kingdom
🇩🇰Department of Oncology, Aalborg University Hospital, Aalborg, Denmark
🇩🇰Department of Oncology Odense University Hospital, Odense, Denmark
Ultrasound-guided LMBB by Caudal-cranial Approach: Radiographic Comparison of a New Ultrasound-guided Method
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- Erasme University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05930236
- Locations
- 🇧🇪
Hôpital Erasme, Bruxelles, Belgium
Effect of Methylprednisolone on Systemic Inflammatory Response During Pediatric Congenital Open-Heart Surgery
Phase 4
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Aga Khan University
- Target Recruit Count
- 60
- Registration Number
- NCT05927233
- Locations
- 🇵🇰
Aga Khan University Hospital, Karachi, Sindh, Pakistan
Methylprednisolone Taper, Lower Extremity
Phase 4
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-05-15
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Emory University
- Target Recruit Count
- 200
- Registration Number
- NCT05859269
- Locations
- 🇺🇸
Emory University Orthopaedics & Spine Hospital, Tucker, Georgia, United States
🇺🇸Emory Musculoskeletal Institute, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath